Fort Worth, TX – October 2, 2024 – Cx Precision Medicine, Inc. (CxPM), developer of AI-powered blood-based tests for neurodegenerative diseases including Alzheimer’s and related dementias, has announced it has been selected as one of the innovative companies to be part of the StartUp Health’s Alzheimer’s Moonshot Program, a global initiative created to develop a collaborative innovation community alongside leading companies, research teams, and stakeholders with mission to accelerate progress in prevention, diagnosis, and management of Alzheimer’s disease and related dementias. 

The Alzheimer’s Moonshot Program, established in January 2024, is a partnership between StartUp Health, the Alzheimer’s Drug Discovery Foundation’s  (ADDF) Diagnostics Accelerator (DxA), and Gates Ventures, the private office of Bill Gates. The program’s goal is to bring together a diverse network of key players to drive innovation and collaboration for the Alzheimer’s community.

“We are excited to be a part of the Alzheimer’s Moonshot Community to enable CxPM to foster many collaborations within the community and bring precision diagnostics to doctors and patients to improve the care of this devastating disease,” said Danguole Altman, CEO of CxPM.

“Being selected to join the Program involved a rigorous evaluation of CxPM, our management team, research and innovation.  We are honored to have been asked to join this powerful network of innovators”

Over 55 million people worldwide are living with Alzheimer disease creating a substantial need for early detection of the disease. CxPM’s technology was developed at Dr. Sid O’Bryant’s laboratory at The University of North Texas Health Science Center (UNTHSC) in Ft. Worth, Texas. Dr. O‘Bryant, PhD., is one of the nation’s pioneers in using blood based biomarkers and predictive algorithms to develop better tools for primary care physicians to accurately diagnose and triage patients with potential signs and symptoms of Alzheimer’s disease and related dementias (ADRD).

About Cx Precision Medicine (CxPM)
CxPM, a transformative diagnostic company, utilizing AI/machine learning and proteomics to accelerate the diagnostic pathway for patients with neurodegenerative disease. CxPM’s NeuroFirst^TM Memory test is the only blood-based test for primary care to rule out ADRD, allowing doctors to triage which patients are unlikely to have dementia and should be evaluated and treated for other causes.

CxPM’s NeuroFirst^TM Memory test decreases unnecessary referrals to specialists and increases diagnostic accuracy.  The underlying technology was developed with extensive NIH funding and exclusively licensed from UNTHSC. Validations will be completed by year end and the test will launch selectively in 2025.  

About Alzheimer’s Moonshot and Startup Health
Startup Health is a mission driven community of families, foundations, researchers, and industry organizations committed to solving big healthcare challenges like Alzheimer’s disease and other dementias. The Alzheimer’s Moonshot Program is a partnership between the Alzheimer’s Drug Discovery Foundation (ADDF), the Diagnostic Accelerator (DxA) and Gates Ventures, the private office of Bill Gates, with initial funding to launch the Alzheimer’s Moonshot provided by Gates Ventures, and DxA. This $100 million global research initiative dedicated to fast-tracking the development of biomarkers and diagnostic tools to aid in early detection and diagnosis of Alzheimer’s disease.

Media Contacts:
Danguole Altman, CEO
[email protected]

Carol Berry, Business Development
[email protected]